Operator
Thank you for standing by. This is the conference operator. Welcome to the Zymeworks conference call and webcast to discuss the acquisition of Theravance Biopharma. [Operator Instructions] The conference is being recorded. [Operator Instructions] I would now like to turn the conference over to Shrinal Inamdar, Vice President of Investor Relations. Shrinal, please go ahead.
Shrinal Inamdar
Vice President of Investor Relations
Good morning, everyone, and thank you for joining us. Today, we will discuss the closing of the Theravance Biopharma Acquisition and what this transaction means for the next phase of Zymeworks. Scott Platshon, our Chief Business Officer, will begin with an overview of the transaction, including YUPELRI and the acquired R&D portfolio and how it advances our strategy at Zymeworks. Kristin Stafford, our Chief Financial Officer, will then discuss the financing structure, financial outlook, and capital allocation framework.
At the end, Ken Galbraith, our CEO and Chair, will open the call for questions. As usual, we will be making forward-looking statements during this call, including statements regarding the Theravance Biopharma acquisition, our financial outlook, the performance and growth of YUPELRI, potential development and commercialization opportunities, future business development, and capital allocation.
These statements are based upon our